Strategic Acquisition NovaBone was recently acquired by Isto Biologics for 60.7M, indicating a strategic consolidation in the bone graft substitutes space and potential for expanded distribution, integration of product lines, and increased sales reach.

Expanded Partnerships Recent long‑term partnerships and collaborations with Summit Products Group and BEGO suggest ongoing opportunities for co‑developed solutions, European launches, and broader channel partnerships to accelerate market penetration.

Regenerative Platform A broad portfolio of FDA‑authorized bioactive bone graft and regenerative products, along with a track record of over two million implantations, signals a mature, trusted platform ripe for value‑added selling of adjunct materials, disposables, and training services.

Clinical Visibility Active participation in major orthopedic events such as AOFAS and IDS demonstrates ongoing clinical validation, surgeon engagement, and opportunities to position premium implants, wedges, putty, and guided workflows to high‑intent buyers.

Tech‑Enabled Growth Investments in digital infrastructure and marketing tools (WordPress/Joomla sites, analytics, CRM‑adjacent tech) enable scalable outreach, targeted campaigns to orthopedic and dental segments, and data‑driven account-based selling.